| DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions M Buscarlet, S Provost, YF Zada, A Barhdadi, V Bourgoin, G Lépine, ... Blood, The Journal of the American Society of Hematology 130 (6), 753-762, 2017 | 390 | 2017 |
| Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera A Tefferi, P Guglielmelli, TL Lasho, G Coltro, CM Finke, GG Loscocco, ... British journal of haematology 189 (2), 291-302, 2020 | 221 | 2020 |
| 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups N Szuber, M Mudireddy, M Nicolosi, D Penna, RR Vallapureddy, ... Mayo Clinic Proceedings 94 (4), 599-610, 2019 | 180 | 2019 |
| Driver mutations and prognosis in primary myelofibrosis: Mayo‐Careggi MPN alliance study of 1,095 patients A Tefferi, M Nicolosi, M Mudireddy, N Szuber, CM Finke, TL Lasho, ... American journal of hematology 93 (3), 348-355, 2018 | 125 | 2018 |
| Targeted next-generation sequencing in blast phase myeloproliferative neoplasms TL Lasho, M Mudireddy, CM Finke, CA Hanson, RP Ketterling, N Szuber, ... Blood advances 2 (4), 370-380, 2018 | 121 | 2018 |
| Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger N Szuber, RR Vallapureddy, D Penna, TL Lasho, C Finke, CA Hanson, ... American journal of hematology 93 (12), 1474-1484, 2018 | 87 | 2018 |
| Mutations and prognosis in myelodysplastic syndromes: karyotype‐adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model N Gangat, M Mudireddy, TL Lasho, CM Finke, M Nicolosi, N Szuber, ... American journal of hematology 93 (5), 691-697, 2018 | 68 | 2018 |
| JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views N Gangat, N Szuber, A Pardanani, A Tefferi Leukemia 35 (8), 2166-2181, 2021 | 63 | 2021 |
| Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases N Gangat, P Guglielmelli, N Szuber, KH Begna, MM Patnaik, MR Litzow, ... American journal of hematology 96 (7), 781-789, 2021 | 63 | 2021 |
| CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival N Szuber, CM Finke, TL Lasho, MA Elliott, CA Hanson, A Pardanani, ... Blood cancer journal 8 (2), 21, 2018 | 50 | 2018 |
| Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management N Szuber, M Elliott, A Tefferi American journal of hematology 95 (2), 212-224, 2020 | 44 | 2020 |
| Chronic neutrophilic leukemia: new science and new diagnostic criteria N Szuber, A Tefferi Blood cancer journal 8 (2), 19, 2018 | 43 | 2018 |
| Mutations and thrombosis in essential thrombocythemia P Guglielmelli, N Gangat, G Coltro, TL Lasho, GG Loscocco, CM Finke, ... Blood cancer journal 11 (4), 77, 2021 | 42 | 2021 |
| Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases S Lavu, N Szuber, M Mudireddy, M Yogarajah, N Gangat, A Pardanani, ... American journal of hematology 93 (3), E61-E64, 2018 | 38 | 2018 |
| JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management N Gangat, N Szuber, A Tefferi American journal of hematology 98 (6), 965-981, 2023 | 34 | 2023 |
| Alternative treatment paradigm for thalassemia using iron chelators N Szuber, JL Buss, S Soe-Lin, H Felfly, M Trudel, P Ponka Experimental hematology 36 (7), 773-785, 2008 | 31 | 2008 |
| Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera E Nguyen, M Harnois, L Busque, S Sirhan, S Assouline, I Chamaki, ... Blood Cancer Journal 11 (4), 75, 2021 | 30 | 2021 |
| MPL-mutated essential thrombocythemia: a morphologic reappraisal N Szuber, CA Hanson, TL Lasho, C Finke, RP Ketterling, A Pardanani, ... Blood cancer journal 8 (12), 121, 2018 | 29 | 2018 |
| JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy N Gangat, N Szuber, H Alkhateeb, A Al-Kali, A Pardanani, A Tefferi Blood, The Journal of the American Society of Hematology 138 (26), 2886-2889, 2021 | 27 | 2021 |
| Driver mutations in primary myelofibrosis and their implications N Szuber, A Tefferi Current Opinion in Hematology 25 (2), 129-135, 2018 | 25 | 2018 |
